BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Has $33.67 Million Stock Position in Danaher Co. (NYSE:DHR)

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its holdings in Danaher Co. (NYSE:DHR) by 60.2% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 134,752 shares of the conglomerate’s stock after acquiring an additional 50,658 shares during the quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in Danaher were worth $33,668,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of DHR. Tsfg LLC boosted its stake in shares of Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after buying an additional 88 shares during the period. nVerses Capital LLC purchased a new position in Danaher in the second quarter valued at about $25,000. CarsonAllaria Wealth Management Ltd. acquired a new position in Danaher in the 2nd quarter worth about $25,000. Cape Investment Advisory Inc. purchased a new stake in shares of Danaher during the 4th quarter worth about $25,000. Finally, Redmont Wealth Advisors LLC acquired a new stake in shares of Danaher during the 1st quarter valued at about $30,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on DHR. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Evercore ISI decreased their price target on Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. TD Cowen boosted their target price on Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, July 24th. Barclays increased their price target on Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a report on Wednesday, July 24th. Finally, Wells Fargo & Company initiated coverage on shares of Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price objective for the company. Seven analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $278.94.

Insider Buying and Selling

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 39,659 shares of company stock worth $11,042,433. Company insiders own 11.10% of the company’s stock.

Danaher Stock Performance

Danaher stock opened at $273.19 on Tuesday. The stock has a 50-day simple moving average of $268.16 and a 200 day simple moving average of $257.32. The stock has a market capitalization of $202.35 billion, a price-to-earnings ratio of 46.30, a P/E/G ratio of 4.48 and a beta of 0.83. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $281.70.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. The firm had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business’s revenue for the quarter was down 2.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.05 earnings per share. On average, research analysts anticipate that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.40%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio is currently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.